Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae has reiterated a Buy rating on Arbutus Biopharma (NASDAQ:ABUS), with a maintained price target of $4.

May 03, 2024 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital reiterates a Buy rating on Arbutus Biopharma with a $4 price target.
The reiteration of a Buy rating by a reputable analyst firm like Chardan Capital, along with a maintained price target, can positively influence investor sentiment towards ABUS. This endorsement may lead to increased investor confidence and potential upward movement in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100